TBC1D8 and ovarian carcinoma: By binding to PKM2, TBC1D8 hinders PKM2 tetramerization to decrease pyruvate kinase activity and promote aerobic glycolysis, leading to ovarian cancer tumorigenesis and metabolic reprogramming (Chen et al., 2019).